Dr. Mark A. Wurth, MD/PHD
Pediatric Pulmonology (Pediatric Pulmonology Physician)
Department Of Pediatrics 740 S Limestone St
Lexington, KY 40536
Who else practices at this address →
Fayette County includes mental health (15% of residents) shortage areas. About shortage areas
At a glance
- Medical school
- University of Kentucky College of Medicine (2008)
- Years since graduation
- 18
- In the NPI registry since
- 2008
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Medical school: University of Kentucky College of Medicine
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Pulmonology Physician primary
KY license 44489 -
Internal Medicine Physician
KY license NA -
Pediatric Allergy/Immunology Physician
KY license 44489 -
Pediatrics Physician
KY license NA
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Kentucky Hospital Lexington, KY
Medical groups
- Kentucky Medical Services Foundation, Inc (967 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $156,753 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis
Vertex Pharmaceuticals Incorporated - A Phase 1, First-in-human Study of Safety, Tolerability, and Pharmacokinetics of VX-828
Vertex Pharmaceuticals Incorporated - Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
Sanofi Pasteur Inc. · Active, not recruiting · NCT06824194
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.